Laboratory parameter profiles among patients with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 6, Issue 2, 2007, Pages 117-123

  Goss, Christopher H ^a,b   Mayer Hamblett, Nicole ^a,b   Kronmal, Richard A ^a,b   Williams, Judy ^b   Ramsey, Bonnie W ^a,b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Adverse events; Clinical trials; Cystic fibrosis; Laboratory values

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PLACEBO; TOBRAMYCIN;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NORMAL VALUE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE;

ADOLESCENT; ALANINE TRANSAMINASE; ANTI-BACTERIAL AGENTS; ASPARTATE AMINOTRANSFERASES; CHILD; CLINICAL TRIALS, PHASE III; CROSS-SECTIONAL STUDIES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; LIVER FUNCTION TESTS; LONGITUDINAL STUDIES; MALE; PLACEBOS; REFERENCE VALUES; TOBRAMYCIN;

EID: 33847719171     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2006.05.012     Document Type: Article

References (16)

1. Rosenstein B.J., and Cutting G.R. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 132 4 (Apr 1998) 589-595
2. Cystic Fibrosis Foundation, Patient Registry 2000 Annual Data Report. Bethesda, Maryland; 2001 (Sept).
3. Franklin H.R., Simonetti G.P., Dubbelman A.C., Bokkel Huinink W.W., Taal B.G., Wigbout G., et al. Toxicity grading systems. A comparison between the WHO scoring system and the Common Toxicity Criteria when used for nausea and vomiting. Ann Oncol 5 2 (Feb 1994) 113-117
4. Trotti A., Byhardt R., Stetz J., Gwede C., Corn B., Fu K., et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47 1 (2000 (Apr 1)) 13-47
5. Goss C.H., Mayer-Hamblett N., Yunker A., Waltz D.A., Kronmal R.A., and Ramsey B.W. Laboratory parameter profiles among patients with cystic fibrosis. Am J Rep Crit Care Med 165 8 (2002) A283
6. Ramsey B.W., Pepe M.S., Quan J.M., Otto K.L., Montgomery A.B., Williams-Warren J., et al. Intermittent administration of inhaled tobramycin in patients with cystic. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 340 1 (1999 (Jan 7)) 23-30
7. Lindblad A., Glaumann H., and Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology 30 5 (1999 (Nov)) 1151-1158
8. Colombo C., Battezzati P.M., Podda M., Bettinardi N., and Giunta A. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. Hepatology 23 6 (1996 (Jun)) 1484-1490
9. Patriquin H., Lenaerts C., Smith L., Perreault G., Grignon A., Filiatrault D., et al. Liver disease in children with cystic fibrosis: US-biochemical comparison in 195 patients. Radiology 211 1 (1999 (Apr)) 229-232
10. Colombo C., Battezzati P.M., Crosignani A., Morabito A., Costantini D., Padoan R., et al. Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology 36 6 (2002 (Dec)) 1374-1382
11. Lenaerts C., Lapierre C., Patriquin H., Bureau N., Lepage G., Harel F., et al. Surveillance for cystic fibrosis-associated hepatobiliary disease: early ultrasound changes and predisposing factors. J Pediatr 143 3 (2003 (Sep)) 343-350
12. Westaby D. Liver and biliary disease in cystic fibrosis. In: Hodson ME, Gadders DM, editors. London: 1995. p. 281-93.
13. Smith A.L., Doershuk C., Goldmann D., Gore E., Hilman B., Marks M., et al. Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr 134 4 (1999 (Apr)) 413-421
14. De B.K., Smet M., and Eggermont E. Treatment of Pseudomonas lung infection in cystic fibrosis with piperacillin plus tobramycin versus ceftazidime monotherapy: preliminary communication. Pediatr Pulmonol 7 3 (1989) 171-173
15. De B.K., and Breysem L. Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis with high or conventional doses of ceftazidime. J Antimicrob Chemother 41 3 (1998 (Mar)) 407-409
16. Goss C.H., Rubenfeld G.D., Ramsey B.W., and Aitken M.L. Clinical trial participants compared to non-participants in cystic fibrosis. Am J Respir Crit Care Med 173 1 (2006 (Jan 1)) 98-104